Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation — High-Grade PitNET or PitNEC?

• Published in: Endocrine pathology Vol. 33; no. 2; pp. 257 - 262
• Main Authors: Saeger, Wolfgang, Mawrin, Christian, Meinhardt, Matthias, Wefers, Annika K., Jacobsen, Frank
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2022; Springer Nature B.V
• Subjects: Bone tumors; Brain cancer; Carcinoma; Endocrinology; Gastrointestinal tract; Medicine; Medicine & Public Health; Metastases; Metastasis; Mitosis; Mutation; Neuroendocrine tumors; Oncology; Pathology; Pituitary; Prolactin; PitNEC; PitNET; Pituitary; Neuroendocrine carcinoma
• ISSN: 1046-3976; 1559-0097; 1559-0097
• DOI: 10.1007/s12022-021-09693-y

We report two pituitary neuroendocrine tumors (PitNETs) with very high Ki67 labeling indices, many mitoses and TP53 mutation (nearly all tumor cell nuclei were positive for p53). One of the tumors had bone and liver metastases. One was a corticotroph cell tumor; the other was a lactotroph tumor. The classification of these tumors is the subject of this discussion. Traditionally, pituitary carcinomas are only diagnosed by demonstration of metastases according to the 2017 WHO classification. In contrast, neuroendocrine neoplasms of the gastrointestinal tract and pancreas are classified as either well differentiated NETs that are graded as G1, G2, and G3 based on proliferation as determined by Ki67 indices of ≤ 3, 3–20 and > 20%, and/or < 2, 2–20, and > 20 mitoses per 10 high-power field respectively, or as neuroendocrine carcinomas (NECs) that are poorly differentiated neoplasms with mitoses > 20/HPF and/or a Ki67 index > 20%. With the reclassificiation of PitNETs, in our opinion, the adequate term for the well-differentiated corticotroph tumor that we report is a PitNET G3, whereas the undifferentiated prolactin tumor should be classified as PitNEC. This report expands the spectrum of pituitary neuroendocrine neoplasms.